

3 M.M.

66-200-42

EF/16-14



EXPRESS MAIL NO.: EL 477 037 728 US

44
15/
NE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Busfield et al.

Confirmation No.: 6846

RECEIVED

Serial No.: 09/610,118

Group Art Unit: 1644

JUN 24 2002

Filed: June 30, 2000

Examiner: Decloux, Amy M. TECH CENTER 1600/2900

For: GLYCOPROTEIN VI AND USES
THEREOF

Attorney Docket No.: 7853-211

AMENDMENT UNDER 37 C.F.R. §1.111

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action, mailed December 18, 2001, and in accordance with Rule 111 of the Rules of Practice, please enter the following amendments and consider the remarks below. Applicants submit herewith: (1) Exhibit A, a marked up version of the paragraphs in the specification amended herein; (2) Exhibit B, a marked up version of the claims amended herein; (3) Exhibit C, a copy the pending claims; (4) Exhibit D, a copy of Express Mail Label No. EL 501 636 596 US; (5) Exhibit E, a copy of the stamped postcard received from the United States Patent and Trademark Office; (6) Exhibit F, a Declaration of Dr. Davinder Gill Under 37 C.F.R. § 1.132; (7) Exhibit G, Jirholt et al., 1998, Gene 215: 471-476; (8) Exhibit H, Soderlind et al., 1999, Immunotechnology 4: 279-285; (9) Exhibit I, International Publication No. WO 98/32845; (10) Exhibit J, Chapter 14 of Harlow et al., eds, 1988, Antibodies A Laboratory Manual, Cold Spring Harbor, New York; (11) Exhibit K, a Statement of Attorneys Applicants Regarding the Permanence and Availability of Deposited Microorganisms; (12) a Petition For Extension Of Time (in duplicate) for 3 months, up to and including June 18, 2002 for responding to the Office Action, accompanied by the appropriate provision authorizing payment of the required fee; (13) an Amendment Fee Transmittal (in duplicate), accompanied by the appropriate provision authorizing payment of the required fee; (14) a Transmittal Of Formal Drawings; (15) the formal drawings (40 sheets, representing Figures 1-27); (16) a Second Information Disclosure Statement (in duplicate), accompanied